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Abstract
Gestational diabetes mellitus (GDM) is a complex metabolic disease involving ge-
netic and environmental factors. Recent studies have underlined its heterogeneity, 
so it is reasonable to divide patients into subpopulations depending on whether an 
insulin secretion or sensitivity defect is predominant. Since testing for GDM is usu-
ally performed in the second trimester, misinterpretation of prediabetes as gestational 
diabetes may occur. As with type 2 diabetes (T2DM), rodent models are needed 
for both GDM and prediabetes, but few do exist. Here, we compared the metabolic 
changes in pregnant normal NMRI mice with those in New Zealand obese (NZO) 
mice. Male animals of this strain are an established model of T2DM, whereas female 
mice of this strain are protected from hyperglycemia and β-cell death. We demon-
strate that female NZO mice exhibited impaired glucose tolerance, preconceptional 
hyperinsulinemia, and hyperglucagonemia without any signs of manifest diabetes. 
The NZO model showed, compared with the NMRI control strain, a reduced prolif-
erative response of the Langerhans islets during pregnancy (3.7 ± 0.4 vs. 7.2 ± 0.8% 
Ki-67-positive nuclei, p = .004). However, oral glucose tolerance tests revealed im-
proved stimulation of insulin secretion in both strains. But this adaption was not 
sufficient to prevent impaired glucose tolerance in NZO mice compared with the 
NMRI control (p =  .0002). Interestingly, glucose-stimulated insulin secretion was 
blunted in isolated primary NZO islets in perifusion experiments. In summary, the 
NZO mouse reflects important characteristics of human GDM and prediabetes in 
pregnancy and serves as a model for subpopulations with early alterations in glucose 
metabolism and primary insulin secretion defect.
K E Y W O R D S
impaired glucose tolerance, polygenic mouse model, prediabetes, pregnancy
1 |  INTRODUCTION
Gestational diabetes mellitus (GDM) is defined as any de-
gree of glucose intolerance with first onset or recognition 
during pregnancy, diagnosed between the second or third 
trimester and clearly differentiates from a preconcep-
tionally existing manifest diabetes (American Diabetes 
Association, 2013, 2019). However, the clinical definition 
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disregards the fact that screening also classifies women as 
GDM patients who already had an undiagnosed preconcep-
tional impaired glucose tolerance but no manifest diabe-
tes. The mechanisms involved are heterogeneous and range 
from impaired β-cell function to insulin resistance with 
hyperinsulinemia. GDM is a complex metabolic disease in 
which both environmental or lifestyle factors and a genetic 
predisposition are involved. There is evidence from obser-
vational studies that modifiable factors like pregravid adi-
posity, physical activity, and dietary patterns are involved 
in pathogenesis (Zhang & Ning, 2011).
During normal pregnancy, hormonal and metabolic 
alterations are observed to meet maternal and fetal de-
mands, which furthermore undergo changes as pregnancy 
progresses. Normally, insulin sensitivity is unchanged or 
increased in first trimester and resistance increases in the 
second or third trimester to supply glucose for the develop-
ing fetus (Di Cianni, Miccoli, Volpe, Lencioni, & Del Prato, 
2003; Stanley, Fraser, & Bruce, 1998). This is compensated 
by adaptive mechanisms of the Langerhans islets, which 
increase both basal and glucose-stimulated insulin secre-
tion during pregnancy (Catalano, 1994; Sorenson & Brelje, 
1997). The conventional view on GDM in recent decades has 
been that the disease is caused by a lack of β-cell adaptation 
and a consequential insufficient insulin secretion. Besides 
secretory defects, reduced insulin receptor binding and 
postreceptor signaling defects were considered to be related 
to the development of GDM (Catalano, 2014; Devlieger, 
Casteels, & Van Assche, 2008; Kühl, Hornnes, & Andersen, 
1985). Due to the heterogeneity of diabetes, subdivision 
into the different types (T1DM, T2DM, GDM, etc.) is often 
not sufficient. As a consequence, a more detailed character-
ization of these patients seems reasonable and stratification 
of T2DM patients might further contribute to improved and 
targeted treatment (Ahlqvist et al., 2018; Tuomi et al., 2014). 
Subtypes of GDM were also characterized and it was shown 
that GDM is a heterogeneous disease as well, depending on 
whether an insulin secretion or sensitivity defect is predom-
inant (Powe et al., 2016). Moreover, it could be shown that 
insulin response increases independently of changes in insu-
lin sensitivity in early pregnancy, which might be associated 
with pregnancy-related hormonal changes (Powe, Huston 
Presley, Locascio, & Catalano, 2019).
To study the pathomechanisms of GDM, numerous an-
imal models are described. These range from surgical and 
chemically induced strategies to nutritional and genetic ma-
nipulations (Pasek & Gannon, 2013). Models showing the 
phenotype of gestational diabetes are often based on knock-
out strategies, for example, monogenic models such as the 
db/+, PrlR±, or FoxM1Δpanc mice (Huang, Snider, & Cross, 
2008; Yamashita et al., 2001; Zhang et al., 2010). Current 
genetic mouse models of GDM exhibit characteristics of the 
human disease including impaired glucose tolerance and a 
decreased β-cell proliferation. However, the db/+ mouse, for 
example, shows hyperphagia and severe obesity, which is not 
evident in humans. Single-gene mutations are suitable for the 
identification of pathways underlying GDM, but often repre-
sent simplified models, as they do not adequately describe the 
complex interaction of the polygenic disease. Surgical, that 
is, partial or total pancreatectomy, and chemically induced di-
abetes due to the administration of streptozotocin or alloxan 
do not appropriately reflect the human disease because they 
lead to a permanent, nonphysiological, and irreversible state 
of diabetes with a severe increase in blood glucose (Pasek & 
Gannon, 2013). Therefore, an unmet need exists for models 
which display the full range and the transient nature of the 
metabolic abnormalities.
To close this gap, our approach was to investigate the suit-
ability of a polygenic mouse model, the New Zealand obese 
(NZO) mouse, as a potential model for human GDM. Early 
studies of male NZO revealed hyperglycemia, impaired glu-
cose tolerance, hyperinsulinemia, and reduced insulin re-
sponse following glucose stimulation (Larkins, 1973; Larkins, 
Simeonova, & Veroni, 1980). Numerous studies using male 
NZO mice have resulted in a well-established model of poly-
genic obesity and T2DM (Kluge, Scherneck, Schürmann, & 
Joost, 2012). However, female mice of this strain are protected 
from hyperglycemia and β-cell death due to the sex hormone 
estrogen. But glycemic control of female NZO impairs follow-
ing long-term administration of high-fat diet or after ovarec-
tomy and animals develop a disease pattern of T2DM similar 
to that of humans (Lubura et al., 2015; Vogel et al., 2013).
There is strong evidence that GDM and T2DM share a 
common pathophysiology, same risk factors like adiposity 
and a family history of diabetes, and a common genetic back-
ground (Cho et al., 2009; Huopio et al., 2013; Robitaille & 
Grant, 2008). Therefore, it is plausible that female NZO mice 
may be considered as a suitable polygenic model to study the 
pathophysiology of GDM, which was the aim of this study. 
In particular, it should be shown whether the NZO mouse 
exhibits impaired glucose tolerance before and/or during 
pregnancy and to what extent insulin secretion is impaired. 
Moreover, we wanted to investigate whether the phenotype 
of female NZO mice can be assigned to one of the different 
subtypes of human GDM or to a preconceptional metabolic 
disorder influenced by pregnancy.
2 |  MATERIAL AND METHODS
2.1 | Animals
All experiments were approved by the ethics committee of 
the Lower Saxony State Office for Consumer Protection and 
Food Safety (Oldenburg, Germany; ethics approval num-
ber: 33.19-42502-04-17/2462; internal ID (05.15) TSB TU 
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BS). Breeding pairs of the NZO (NZO/HIBomDife) and the 
NMRI (NMRI/RJ) control strain were provided from the 
German Institute of Human Nutrition (Nuthetal, Germany) 
and further kept and mated in an own breeding. This strain 
was chosen as a suitable control, since female NMRI mice 
represent a control with high body weight without diabetes 
and have a large litter size, which results in a high stimu-
lation of Langerhans islets during pregnancy. Moreover, it 
represents a robust model of normal β-cell physiology. Mice 
were housed in an air-conditioned room at 21 ± 1°C with a 
12:12  hr light-dark cycle (lights on at 06:30 am). Animals 
had ad libitum access to water and food (1328 P, Altromin) 
with a content of 11% fat, 24% protein, and 65% carbohy-
drates with a total metabolizable energy of 13.5 kJ/g. Female 
NZO and NMRI mice were mated over night at the age of 
about 7 weeks. Pregnancy was confirmed by examining vagi-
nal plugs the following morning. This day was considered as 
day 0.5 and mice were studied on day 14.5 of gestation at the 
age of about 9 weeks. The preconceptionally examined group 
was of the same age as the pregnant one. These animals were 
used for perifusion experiments, measurement of plasma and 
pancreatic hormone concentrations, and histological analy-
ses (see below). For in vivo experiments, the same animals 
throughout were studied over the period of time specified 
below to determine alterations of blood glucose levels, glu-
cose tolerance, insulin secretion, and sensitivity. Postpartum 
OGTT was performed about 4 weeks after birth of offspring. 
Lactation lasted 3 weeks and the offspring were weaned after 
this period. Different animals were used for the individual 
experiments, that is, OGTT, immunohistochemistry, total 
pancreatic hormone content, and islet isolation.
2.2 | Oral glucose tolerance tests 
(OGTT) and determination of in vivo 
insulin secretion
After 6 hr of food deprivation, basal blood glucose, plasma 
insulin concentrations, and body weights of NZO and NMRI 
mice were determined. Each animal received an oral glu-
cose bolus of 2 mg glucose/ g body weight by gavage. These 
OGTT conditions were recommended to achieve robust dif-
ferences in blood glucose and plasma insulin concentrations 
(Andrikopoulos, Blair, Deluca, Fam, & Proietto, 2008). At 
time points 7.5, 15, 30, 60, and 120  min after application, 
blood glucose was measured from the tail tip using a glu-
cose meter (Contour next, Ascensia Diabetes Care). At each 
time point, blood samples were collected from tail tip into 
heparin-coated microtubes (Sarstedt) and kept on ice. After 
centrifugation, plasma samples were stored at −80°C for 
later insulin measurement. Keeping stress as low as possible, 
mice were kept in their usual cages during the test and had 
free access to water.
2.3 | Plasma hormone concentrations
Random plasma hormone concentrations were measured in 
animals fed ad libitum and postabsorptive concentrations 
after 6 hr of food deprivation. Blood was collected via the 
vena cava or the heart in deep anesthesia followed by a cer-
vical dislocation. After centrifugation, plasma samples were 
stored at −80°C for later measurements. Plasma insulin con-
centrations were determined by Mouse Ultrasensitive Insulin 
ELISA according to manufacturer's protocol (ALPCO). 
Plasma glucagon concentrations were determined by 
Glucagon ELISA (Mercodia).
2.4 | Indices of insulin sensitivity
Homeostasis model assessment of insulin resistance 
(HOMA-IR), a surrogate marker of insulin resistance, was 
calculated as (fasting glucose concentration x fasting insu-
lin concentration)/ 22.5 (Matthews et al., 1985). To evalu-
ate whole body insulin sensitivity from data obtained during 
oral glucose tolerance test, Matsuda index was calculated as 
(10,000/ √ (fasting insulin × fasting glucose × mean insulin 
during OGTT × mean glucose during OGTT)) (Matsuda & 
DeFronzo, 1999).
2.5 | Total pancreatic hormone content
Tissues were collected from animals fed ad libitum after 
cervical dislocation. After sampling, pancreas was weighed, 
quickly frozen in liquid nitrogen, and stored at −80°C for 
further processing. Whole pancreas was homogenized in ice-
cold acid ethanol (0.18 M HCl in 70% ethanol) and incubated 
over night at 4°C. After centrifugation (5,000  g, 15  min, 
4°C), supernatants were stored at −20°C for later measure-
ments using Mouse High Range Insulin ELISA (ALPCO) 
and Glucagon ELISA (Mercodia) according to manufactur-
er's protocols.
2.6 | Immunohistochemistry and 
immunofluorescence of pancreatic sections
Pancreatic tissues were obtained from animals fed ad libitum 
after cervical dislocation and fixed in 4% phosphate buffered 
formaldehyde for 24 hr. Fixed tissues were then embedded in 
paraffin according to standard procedures. Serial sections of 
4 μm at sampling intervals of 150 μm were prepared. After re-
hydration, immunohistochemical staining was carried out on 
three sections, using rabbit polyclonal anti-glucagon antibody 
(1:200; Cell Marque), rabbit polyclonal anti-somatostatin an-
tibody (1:2,000; Abcam), and rabbit monoclonal anti-Ki-67 
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antibody (1:250; Cell Marque). Prior to staining of Ki-67 an-
tibody, heat-mediated antigen retrieval was performed, using 
a citrate buffer at pH 6.0 (Dako REALTM Target Retrieval 
Solution; Dako, Agilent Technologies). Secondary antibody was 
Histofine Simple Stain Mouse MAX PO anti-rabbit (Nichirei 
Biosciences), detected by diaminobenzidine (Dako) according 
to manufacturer's instructions. Nuclei were then stained with 
Mayer's hematoxylin. The microscopic evaluation was carried 
out on basis of three sectional planes per animal. To determine 
glucagon and somatostatin areas, one hundred islets per strain 
and condition (n = 4–6 animals per group) were randomly se-
lected. Evaluation of glucagon and somatostatin area was per-
formed with the upright microscope Eclipse Ni-E (Nikon), 
equipped with the DS-Fi3 Color Camera (Nikon) and analysis 
software NIS elements AR 5 (Nikon). Evaluation of Ki-67-
positive islet cells was performed with the upright microscope 
Leitz Orthoplan (Leitz), equipped with VisiCAM 100 (Visitron 
Systems GmbH) and the software VisiVIEW (Visitron Systems 
GmbH). When evaluating Ki-67, all islets of three sectional 
planes per animal (n = 5–6 animals per group) were considered 
and manual counting of Ki-67-positive nuclei was conducted 
using ImageJ software (Rasband, 2011). In addition, double 
immunofluorescence staining for insulin (mouse monoclonal 
anti-insulin antibody; 1:50,000; Sigma-Aldrich) and glucagon 
(1:100, Cell Marque) was performed on representative pan-
creatic slices. Primary antibodies were detected with fluoro-
phore-labeled secondary antibodies using Rhodamine Red-X 
goat anti-mouse (1:200, Jackson ImmunoResearch) and Alexa 
Fluor488 goat anti-rabbit (1:500, Jackson ImmunoResearch) 
plus DAPI (KPL). Acquisition of representative images was 
performed with the upright microscope Eclipse Ni-E (Nikon), 
equipped with the DS-Fi3 Color Camera (Nikon) and analysis 
software NIS elements AR 5 (Nikon).
2.7 | Glucose-stimulated insulin secretion of 
primary mouse islets
Islets were isolated by a collagenase digestion technique from 
animals fed ad libitum after cervical dislocation (Collagenase 
P, Roche; 0.5 mg/ml) in HEPES-buffered Krebs-Ringer me-
dium (115 mM NaCl, 4.7 mM KCl, 2.6 mM CaCl2, 1.2 mM 
KH2PO4, 1.2 mM MgSO4, 20 mM NaHCO3, 10 mM HEPES, 
and 2 mg/ml BSA) which was saturated with 95% O2 and 5% 
CO2, containing 5 mM glucose. Briefly, the pancreas was in-
flated by injection of 3 ml collagenase solution into the com-
mon bile duct. Subsequently, the pancreas was digested for 
8:45 min in a water bath at 37°C and shaken vigorously for 
1 min. Digestion was stopped by adding ice-cold Krebs-Ringer 
medium and washed twice with centrifugation steps in between 
(300  g, 15  s). Islets were passaged several times in Krebs-
Ringer medium to remove exocrine pancreatic parts by hand-
picking under the stereomicroscope. Fifty freshly isolated islets 
were then given into a purpose-made perifusion chamber and 
perifused with a rate of 1 ml/min at a temperature of 37°C. The 
perifusion medium consisted of HEPES-buffered Krebs-Ringer 
medium with different glucose concentrations (5 and 20 mM). 
The efflux was collected at defined time intervals and insulin 
secretion was determined by Rat Insulin ELISA (Mercodia) 
(Hatlapatka, Willenborg, & Rustenbeck, 2009).
2.8 | Statistical analysis
For statistical analysis and graphical presentation GraphPad 
Prism 7 (GraphPad) was used. Data are presented as 
means  ±  SEM. Nonparametric Mann–Whitney U test was 
applied to compare means of both mouse strains separately 
for each of the time points or to compare differences within 
one strain over the period of time (e.g., NMRI preconcep-
tional vs. d 14.5). This test was used for the following param-
eters: Figure 3b: AUC of insulin secreted during perifusion. 
Figure 4a: body weight, b: number of pups, c: random blood 
glucose, d: postabsorptive blood glucose, e: random plasma 
insulin, f: postabsorptive plasma insulin, g: HOMA-IR, and 
h: Matsuda ISI. Figure 5a: Ki-67-positive cells, b: islet size, 
c: insulin content, d: glucagon content, e: glucagon area, and 
f: somatostatin area. Figure 7a: random plasma glucagon and 
b: postabsorptive plasma glucagon. To evaluate alterations 
within one strain over the period of time (e.g., NMRI precon-
ceptional vs. d 14.5 vs. postpartum) and alterations of insulin 
secretion during OGTT, Kruskal–Wallis H test followed by 
Dunn's multiple-comparison test was used for the following 
parameters: Figure 1d: AUC of blood glucose and h: AUC 
of insulin secreted during OGTT. Figure 2a-f: insulin secre-
tion during the first 30 min of OGTT. A value of p < .05 was 
considered statistically significant. P values were indicated 
as *p < .05, **p < .01, ***p < .001, and ****p < .0001.
3 |  RESULTS
3.1 | Impaired glucose tolerance but 
improved responsiveness of islets of 
Langerhans in pregnant NZO mice
To determine glucose tolerance in vivo (Figure  1a-c), mice 
were deprived of food for 6 hr and an OGTT was performed 
administering 2 mg glucose/g body weight. NZO mice showed 
impaired glucose tolerance with increased blood glucose excur-
sions after stimulus compared with the control strain preconcep-
tionally, on day 14.5 of gestation and postpartum. This is also 
reflected in significant increases in the AUC (Figure 1d) (NZO 
vs. NMRI; preconceptional: 31,321 ± 1,218 vs. 19,594 ± 784  
mg/dl  ×  120  min, p  =  <.0001; day 14.5:  27,106  ±  662 vs. 
16,627  ±  651  mg/dl  ×  120  min, p  =  .0002; postpartum: 
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30,087 ± 1,413 vs. 18,658 ± 854 mg/dl × 20 min, p = .0005). 
In addition, plasma samples were taken to determine insulin 
secretion in vivo. Insulin secretion was not stimulated in NZO 
mice by glucose preconceptionally (Figure 1e and Figure 2d), 
while the same glucose challenge had a significantly insulino-
tropic effect during pregnancy (Figure 1f and Figure 2e). This 
was associated with significant decreases in the fasting insu-
lin values (NZO preconceptional vs. day 14.5: 1.65 ± 0.32 vs. 
0.56 ± 0.13 µg/L, p = .0008). Postpartum, basal insulin secre-
tion increased again in NZO mice and was not stimulated by 
glucose (Figure 1g and Figure 2f). Compared with the NZO 
strain, NMRI control mice showed a significant increase in in-
sulin secretion after glucose application at all three time points. 
During pregnancy this was even more pronounced (Figure 2a-
c). Total amount of insulin secreted during OGTT, expressed as 
AUC, was increased in the NZO strain at all three time points 
(Figure 1h) (NZO vs. NMRI; preconceptional: 172.7 ± 19.3 vs. 
53.5 ± 8.0 µg/l × 120 min, p = <.0001; day 14.5: 117.7 ± 15.7 
vs. 88.8 ± 10.3 µg/l × 120 min, ns; postpartum: 137.4 ± 12.7 
vs. 47.7 ± 8.5 µg/l × 120 min, p = .0006).
3.2 | Isolated Langerhans islets of NZO 
mice did not respond adequately to a 
glucose stimulus
To investigate insulin secretion under exclusion of systemic 
influences, primary Langerhans islets were isolated and ki-
netics were determined in perifusion experiments (Figure 3a). 
Compared with NZO, NMRI islets secreted significantly higher 
amounts of insulin at both time points. During pregnancy, in-
crease in insulin secretion after stimulus was prompt and 
showed a steeper increase within this strain. Preconceptionally, 
freshly isolated NZO mouse islets showed weak secretory 
F I G U R E  1  Impaired glucose 
tolerance and preconceptional 
hyperinsulinemia in female NZO mice. 
Blood glucose and plasma insulin 
concentrations during oral glucose tolerance 
tests of NZO mice (black circles) and NMRI 
control mice (white squares).  
(a, e) Preconceptional, (b, f) day 14.5 of 
gestation, and (c, g) postpartum. (d) Area 
under the curve (AUC) for blood glucose 
calculated using the trapezoidal rule of NZO 
mice (black bars) and NMRI control mice 
(white bars). (h) AUC for insulin secreted 
during OGTT of NZO and NMRI control 
mice. Squared parts of the bars indicate 
first phase (0–30 min) of insulin secretion. 
Data are presented as means ± SEM 
(n = 7–11 animals per group). ***p < .001, 
****p < .0001, NMRI postpartum vs. day 
14.5: §p = .0183














































































































































6 of 13 |   GRUPE Et al.
response to the increase in glucose from 5 mM to 20 mM. In 
contrast to the in vivo experiments, this reduced responsive-
ness was unchanged on day 14.5 of gestation. Prestimulatory 
values of insulin secretion after 60  min of perifusion with 
medium containing 5 mM glucose were not significantly dif-
ferent at both time points (NZO vs. NMRI, preconceptional: 
6.45  ±  1.40 vs. 4.06  ±  0.34  pg/min  ×  islet, ns; day 14.5 of 
gestation: 5.86 ± 0.70 vs. 3.71 ± 0.38 pg/min × islet, ns). Total 
amount of insulin released during stimulation for 60 min, pre-
sented as AUC (Figure  3b), was significantly higher within 
the NMRI strain (NZO vs. NMRI, preconceptional: 711 ± 28 
vs. 1,715 ± 68 pg × 60 min, p = .029; day 14.5 of gestation: 
506 ± 75 vs. 1,849 ± 305 pg × 60 min, p = .008). During preg-
nancy, a slight but not significant decrease in insulin secretion 
was observed compared with preconceptional findings within 
the NZO strain (p = .06). This was primarily due to a signifi-
cantly reduced second phase of insulin secretion, whereas this 
phase remained almost unchanged within the control strain.
3.3 | Pregnancy improved preconceptional 
hyperinsulinemia of NZO mice
Preconceptionally, body weights were comparable be-
tween NZO mice and the NMRI control strain. During 
pregnancy, a substantial weight gain was observed in 
the control strain, whereas body weights of NZO mice 
increased only moderately (Figure  4a). This was due to 
a higher number of offspring in NMRI control mice. The 
average litter size in NMRI was 14 and 8 in NZO mice 
(Figure 4b). Birth weights of the offspring of both strains 
were comparable (data not shown). Random blood glucose 
levels were determined at time points preconceptional and 
on day 14.5 of gestation. The NZO mouse showed no overt 
hyperglycemia at any time point (Figure 4c). During preg-
nancy, blood glucose concentrations were slightly but not 
significantly lower than preconceptionally in both strains. 
Postabsorptive blood glucose concentrations (Figure  4d) 
were also not significantly different between the strains 
and slightly lower during pregnancy. Preconceptionally, 
random plasma insulin concentrations (Figure 4e) were sig-
nificantly higher in NZO mice compared with the control 
(NZO vs. NMRI: 2.1 ± 0.4 vs. 0.6 ± 0.2 µg/L, p = .004). 
During pregnancy, random plasma insulin concentrations 
slightly increased in control mice and decreased in NZO 
mice (NZO vs. NMRI: 1.2 ± 0.3 vs. 1.2 ± 0.6 µg/L, ns). 
Postabsorptive insulin concentrations (Figure  4f) were 
similar in their profiles. Preconceptional hyperinsuline-
mia of the NZO was more pronounced, improving sig-
nificantly during pregnancy (NZO preconceptional vs. day 
14.5:  1.6  ±  0.3 vs. 0.6  ±  0.1  µg/L, p  =  .0008). During 
OGTT, insulin secretion of NZO increased notably after the 
first phase, indicating insulin resistance. This observation 
was supported by calculating the HOMA-IR (Figure  4g) 
F I G U R E  2  Detailed bar chart of Figure 1e–g highlighting the improved stimulation of insulin secretion in NZO mice during pregnancy. 
Insulin secretion during the first 30 min of OGTT at time points (a, d) preconceptional, (b, e) day 14.5 of gestation, and (c, f) postpartum of 
NMRI (upper graphs) and NZO mice (lower graphs). Data are presented as means ± SEM (n = 7–11 animals per group). *p < .05, **p < .01, 
***p < .001
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and Matsuda index for insulin sensitivity (Figure  4h). 
Preconceptionally, HOMA and Matsuda indices differed 
significantly between the two strains, implying increased 
insulin resistance (NZO vs. NMRI: 12.34  ±  3.09 vs. 
1.98 ± 0.44, p = .0001) and decreased insulin sensitivity 
of the NZO (NZO vs. NMRI: 1.85 ± 0.25 vs. 10.03 ± 1.84, 
p = <.0001). During pregnancy, HOMA and Matsuda indi-
ces did not differ between NZO and NMRI mice (NZO vs. 
NMRI: HOMA: 3.86 ± 0.99 vs. 2.63 ± 0.37, ns; Matsuda: 
4.36 ± 0.63 vs. 6.03 ± 0.50, ns), since insulin resistance 
decreased and insulin sensitivity increased significantly in 
NZO. Within the NMRI control strain insulin resistance 
increased and insulin sensitivity decreased slightly but 
not significantly, reflecting the natural adaptation during 
pregnancy.
3.4 | Improved responsiveness during 
pregnancy was not a cause of enhanced islet 
cell proliferation
To determine adaptive changes in Langerhans islets dur-
ing pregnancy, pancreata were examined immunohisto-
logically at time points preconceptional and on day 14.5 of 
gestation. The proliferation marker Ki-67 (Figure  5a) was 
used to determine the proliferative response of Langerhans 
islets to the increased insulin demand during pregnancy. 
Preconceptionally, Ki-67-positive islet cells were not sig-
nificantly different between the strains (NZO vs. NMRI: 
3.1 ± 0.6 vs. 2.4 ± 0.5%, ns). On day 14.5 of gestation, islet 
cells of NZO mice showed significantly lower proliferation 
in comparison to the NMRI control strain (NZO vs. NMRI: 
3.7 ± 0.4 vs. 7.2 ± 0.8%, p = .004). So, in contrast to NZO, 
a significant increase in proliferation could be observed 
during pregnancy in the NMRI control strain (2.4  ±  0.5 
vs. 7.2  ±  0.8%, p  =  .002). Mean islet size (Figure  5b) of 
NZO and NMRI control mice was not significantly dif-
ferent at both time points. During pregnancy, islet size in-
creased within the NMRI control strain (16,601 ± 2,162 vs. 
21,987 ± 2,276 µm2, p = .031). Also in NZO mice islet size 
increased slightly, but not significantly (14,382 ± 1,635 vs. 
19,437 ± 2,062 µm2, p =  .063). To estimate β-cell mass, 
total pancreatic insulin content (Figure  5c) was deter-
mined in acid-ethanol extracts. At both time points, in-
sulin contents did not differ significantly between the 
two strains, but were moderately higher in NZO mice. 
During pregnancy, insulin contents increased slightly in 
both strains. Preconceptionally, total pancreatic gluca-
gon content (Figure 5d) was slightly higher in NZO mice, 
decreased insignificantly on day 14.5 of gestation within 
this strain, but increased slightly in NMRI control mice 
(NZO: 1,034 ± 153 vs. 887 ± 50 ng/pancreas, ns; NMRI: 
831  ±  93 vs. 948  ±  143  ng/pancreas, ns). The percent-
age of glucagon positive area of total islet size (Figure 5e) 
was markedly increased within the NZO at both time 
points. In NZO and NMRI control mice, glucagon-posi-
tive area decreased significantly during pregnancy (NZO: 
16.7 ± 0.9 vs. 14.0 ± 0.8%, p = .041; NMRI: 12.5 ± 0.7 vs. 
9.9 ± 0.7%, p = .001). Comparing the somatostatin-posi-
tive area (Figure  5f), no significant differences between 
both strains were observed. In NZO mice, somatostatin 
increased slightly but not significantly during pregnancy 
(4.8 ± 0.4 vs. 5.7 ± 0.7%, p = .95) and decreased signifi-
cantly in NMRI mice (5.1 ± 0.3 vs. 4.5 ± 0.4%, p = .018). 
Immunohistochemistry and immunofluorescence revealed 
a differing α-cell distribution pattern in Langerhans islets 
between both strains. In NZO mice, α-cells were located 
peripherally as well as randomly in the core of the islet. 
The NMRI control strain showed a peripheral distribution 
pattern of α-cells (Figure 6a,b).
F I G U R E  3  Insulin secretion defect of freshly isolated NZO 
islets. (a) Insulin secretion at time points preconceptional and day 
14.5 of gestation of NZO mice (preconceptional: black line, black 
circles; d 14.5: grey line, black circles) and NMRI control mice 
(preconceptional: black line, white squares; d 14.5: grey line, white 
squares). Islets were perifused from 0 min to 60 min with medium 
containing 5 mM glucose. Then glucose concentration was raised 
to 20 mM for 40 min of perifusion, followed by a wash out period 
of 20 min at 5 mM glucose. (b) Area under the curve (AUC) was 
calculated using the trapezoidal rule (NZO: black bars; NMRI: white 
bars). Data are presented as means ± SEM (n = 4–5 animals per 
group). *p < .05, **p < .01



















































8 of 13 |   GRUPE Et al.
3.5 | Pregnancy improved preconceptional 
hyperglucagonemia in NZO mice
Random plasma glucagon levels (Figure 7a) revealed pre-
conceptional hyperglucagonemia of the NZO mouse (NZO 
vs. NMRI: 17.44 ± 7.47 vs. 3.68 ± 0.46 pmol/L, p = .069). 
Postabsorptive glucagon concentrations (Figure  7b) were 
similar in their profiles. A slight increase within the con-
trol strain during pregnancy was observed, whereas lev-
els decreased slightly but not significantly in NZO mice 
(preconceptional vs. day 14.5, NZO: 2.60  ±  0.85 vs. 
1.11  ±  0.20  pmol/l, p  =  .064; NMRI: 1.31  ±  0.25 vs. 
1.69 ± 0.27 pmol/l, ns).
4 |  DISCUSSION
Adaptive mechanisms of Langerhans islets to an increased 
insulin demand during pregnancy, glucose tolerance, and 
insulin secretion profiles in vivo and ex vivo were evaluated 
in the polygenic NZO mouse model and compared with the 
NMRI control strain. The data describe the phenotype of fe-
male NZO mice prior to conception, during gestation, and 
postpartum and affirm that the NZO strain displays important 
characteristics of subpopulations of human GDM and/or pre-
diabetes in pregnancy. This underlines the heterogeneity of 
the metabolic disease.
NZO mice showed no overt hyperglycemia but exhib-
ited impaired glucose tolerance. Preconceptionally impaired 
glucose tolerance did not deteriorate during pregnancy and 
persisted postpartum. GDM, in the strict sense, is defined as 
impaired glucose tolerance with first recognition during preg-
nancy, diagnosed by 75-g OGTT. Since in humans an OGTT 
is routinely performed only between the second and third tri-
mester of pregnancy, data from preconceptional tests are rare 
and were often obtained from cohorts with specific risk factors 
(Catalano et al., 1993). Limited data are available from women 
affected by polycystic ovarian syndrome (PCOS) or fertility 
F I G U R E  4  Insulin resistance without 
manifest diabetes in female NZO mice. (a) 
Body weights of NZO and NMRI control 
mice at time points preconceptional (white 
bars) and day 14.5 of gestation (black 
bars). (b) Number of pups of NZO (black 
bars) and NMRI control mice (white bars). 
(c) Random and (d) postabsorptive (6 hr 
food deprivation) blood glucose of NZO 
and NMRI control mice at time points 
preconceptional (white bars) and day 14.5 
of gestation (black bars). (e) Random and (f) 
postabsorptive plasma insulin concentrations 
of both strains. (g) Calculation of insulin 
resistance by the homeostasis model 
assessment method (HOMA-IR) and (h) 
Matsuda index of insulin sensitivity (ISI) 
of NZO and NMRI control mice. Data are 
presented as means ± SEM (a and b n = 10, 
c and e n = 5–7, d, f, g, and h n = 7–11 
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disorders and the desire to become pregnant (Lanzone et al., 
1996; Wei et al., 2008, 2017). It is known that women having 
PCOS represent a heterogeneous subgroup which is at higher 
risk to develop impaired glucose tolerance, both preconcep-
tionally and during pregnancy (Lanzone et al., 1996). There 
is an association between preconceptional impaired glucose 
tolerance and adverse pregnancy outcome, independent from 
BMI (Wei et al., 2017). Furthermore, it could be shown that 
preconceptionally elevated plasma insulin concentrations 
increase the risk of glycemic disorders during pregnancy, 
although PCOS patients significantly increased secretion to 
compensate for higher insulin requirement (Lanzone et al., 
1995). When screening for women with early manifestation 
of GDM, it was found that these women had elevated AUCs 
F I G U R E  5  Different adaptation of 
Langerhans islets in NZO and NMRI mice 
during gestation. (a) Mean percentage of 
islet cells positive for Ki-67 and (b) islet 
size of NZO and NMRI control mice at both 
time points, preconceptional (white bars), 
and on day 14.5 of gestation (black bars). 
(c) Total pancreatic insulin and (d) glucagon 
contents were determined in acid-ethanol 
extracts. (e) Mean percentage of islet cells 
positive for glucagon and (f) somatostatin. 
Data are presented as means ± SEM 






































































































































F I G U R E  6  Different α-cell distribution in female NZO mice. (a) Representative images showing glucagon-positive islet cells 
(brown) of NZO and NMRI control mice at time points preconceptional and on day 14.5 of gestation. (b) Representative images of a double 
immunofluorescence staining for insulin (red) and glucagon (green) at time points preconceptional and on day 14.5 of gestation. Nuclei were 
stained with DAPI (blue). Scale bars: 100 µm
a b
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of glucose and insulin during OGTT compared with women 
with late manifestation or normal glucose tolerance (Bozkurt 
et al., 2015). Also NZO mice showed early hyperinsulinemia, 
impaired glucose tolerance, and insulin secretion could not 
be stimulated by glucose. During pregnancy, fasting insulin 
values were significantly lower and comparable with the val-
ues of the NMRI control strain. In addition, the application 
of glucose had a significantly insulinotropic effect in female 
NZO with a distinct first phase of insulin secretion, which 
could not be observed prior to conception. AUC of first phase 
insulin secretion during OGTT between both strains was 
comparable during pregnancy. Besides significantly reduced 
hyperinsulinemia, an improvement of insulin resistance and 
sensitivity during pregnancy of the NZO strain, was found.
In contrast to in vivo experiments, freshly isolated primary 
islets of the NZO strain showed weak secretory response in 
perifusion experiments, both preconceptionally and on day 
14.5 of gestation. AUC of insulin secreted during perifusion 
experiments was significantly higher in NMRI control mice 
at both time points. Compared with the in vivo experiments, 
an improvement of insulin secretion could not be observed ex 
vivo. It is reasonable to assume that extrapancreatic modula-
tors such as pregnancy hormones or the interaction of periph-
eral organs have a beneficial effect on insulin secretion and 
glucose homeostasis. Besides pregnancy hormones, changes 
in cytokine concentrations also affect insulin sensitivity. 
Alterations in pro- and anti-inflammatory cytokine concen-
trations, such as adiponectin, leptin, and TNFα, have been 
observed in women affected by GDM (Fasshauer, Blüher, & 
Stumvoll, 2014; Wedekind & Belkacemi, 2016). In humans, 
increased TNFα and decreased adiponectin serum concentra-
tions are associated with GDM (Cseh et al., 2004; Guillemette 
et al., 2014; Kinalski, Telejko, Kuzmicki, Kretowski, & 
Kinalska, 2005). Since adipose tissue, which secrets TNFα, 
is elevated in NZO mice, influences of cytokines on insulin 
secretion would also be conceivable and provide an approach 
for further investigations.
The most important finding of histological analysis was 
a significant increase in islet cell proliferation solely in the 
NMRI control strain, whereas proliferation remained almost 
unchanged in NZO islets. Despite the proliferation defect, in 
vivo insulin response improved during pregnancy in NZO 
mice. Which role pregnancy-associated hormones may have 
is arguable, as increased insulin secretion and proliferation 
correlate with their secretion (Parsons, Brelje, & Sorenson, 
1992; Sorenson & Brelje, 1997). NZO mice showed no differ-
ences in plasma prolactin concentrations compared with the 
control strain both preconceptionally and during pregnancy 
(data not shown). For this reason, improved responsiveness 
of the NZO mouse cannot be solely explained by this preg-
nancy-associated hormone and the underlying mechanisms 
have to be further investigated. Changes in insulin content 
cannot be a reason either, as this remains unaffected by preg-
nancy, with a trend toward elevated levels in the NZO strain 
at both time points.
In male NZO mice, a model of T2DM, it was shown that 
under glucotoxic conditions proliferation of β-cells could 
not be initiated in comparison to diabetes-resistant B6-ob/
ob and candidate genes of this defect were identified (Kluth 
et al., 2015). Even in healthy women, pregnancy is a diabe-
togenic condition associated with reduced insulin sensitivity 
and therefore requires a compensatory increase in β-cell mass 
and function (Di Cianni et al., 2003). Since T2DM and gesta-
tional diabetes have similar genetic reasons (Cho et al., 2009; 
Huopio et al., 2013; Robitaille & Grant, 2008), it is conceiv-
able that this proliferation defect of male NZO is also present 
in female animals.
The physiologically increasing insulin resistance 
during pregnancy facilitates the supply of energy to the 
fetus and therefore insulin requirements rise continuously 
(Lain & Catalano, 2007). Functionally effective β-cell 
mass increases as a result of hyperplasia and hypertrophy. 
These adaptive mechanisms during pregnancy are regu-
lated by lactogenic hormones such as placental lactogen 
F I G U R E  7  Preconceptional hyperglucagonemia in female 
NZO mice. (a) Random and (b) postabsorptive (6 hr food deprivation) 
plasma glucagon concentrations of NZO and NMRI control mice at 
both time points, preconceptional (white bars) and on day 14.5 of 
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and prolactin (Parsons et al., 1992; Sorenson & Brelje, 
1997). In addition, serotonin, which is produced and se-
creted in high concentrations during pregnancy, regulates 
β-cell proliferation and inhibition of its synthesis leads 
to impaired glucose tolerance (Kim et al., 2010). An in-
crease in islet area during pregnancy could also be shown 
in the strains examined here, albeit to a greater extent in 
the NMRI control strain. This was associated with a sig-
nificant decrease in the percentage of glucagon and so-
matostatin areas in the NMRI control strain. Due to the 
expansion of islet area, with simultaneous reduction in α- 
and δ-cell proportions, it can be assumed that functional 
β-cell area increased as an adaptive mechanism. There was 
only a significant decrease in glucagon area within the 
NZO strain, whereas somatostatin area increased slightly 
but not significantly. These observations imply an increase 
in β-cell area, although of lower magnitude than in the 
control strain. There was an interesting observation of 
the α-cell distribution pattern in Langerhans islets within 
the NZO strain. α-cells were located peripherally as well 
as randomly in the core of the islet, whereas the control 
strain showed a peripheral distribution pattern. A periph-
eral α-cell distribution reflects the normal physiology 
of mouse islets. However, increased insulin demands, as 
known from prediabetes or insulin resistance, lead to an 
occurrence of α-cells inside the core. An improved vas-
cularization with more efficient cell–cell communication 
and thus an improved sensitivity for changes in glucose 
concentration are possible underlying reasons (Kharouta 
et al., 2009; Steiner, Kim, Miller, & Hara, 2010). These 
early alterations in islet architecture could therefore in-
fluence the prediabetic metabolism with preconceptional 
hyperinsulinemia, hyperglucagonemia, and insulin resis-
tance in NZO mice. It is known that glucagon stimulates 
insulin secretion by activation of glucagon and GLP-1 
receptors on β-cells (Kawai, Yokota, Ohashi, Watanabe, 
& Yamashita, 1995; Svendsen et al., 2018). We observed 
a trend toward a decline in plasma and total pancreatic 
glucagon concentrations during pregnancy in NZO mice. 
This could also affect preconceptional hyperinsulinemia, 
which improved during pregnancy.
In summary, our data indicate that NZO mice exhibit 
important characteristics of human gestational diabetes. 
Nonetheless, due to the heterogeneity of the disease, only 
certain subpopulations may be represented. Patients with 
early alterations in glucose metabolism, impaired glu-
cose tolerance, and lack of compensatory adaptation of 
Langerhans islet should be emphasized here. Furthermore, 
patients already suffering from prediabetes prior to preg-
nancy and diagnosed as GDM patients during pregnancy 
can be considered. Glucose-stimulated insulin secretion 
differed significantly between in vivo experiments, in 
which responsiveness of insulin secretion improved during 
pregnancy, and ex vivo experiments without any change 
in secretion. The underlying mechanisms, in which preg-
nancy-associated hormones such as serotonin and cyto-
kines can be of decisive importance, are subject of further 
investigation.
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